Literature DB >> 10066160

Genetic polymorphisms of human N-acetyltransferase, cytochrome P450, glutathione-S-transferase, and epoxide hydrolase enzymes: relevance to xenobiotic metabolism and toxicity.

L W Wormhoudt1, J N Commandeur, N P Vermeulen.   

Abstract

In this review, an overview is presented of the current knowledge of genetic polymorphisms of four of the most important enzyme families involved in the metabolism of xenobiotics, that is, the N-acetyltransferase (NAT), cytochrome P450 (P450), glutathione-S-transferase (GST), and microsomal epoxide hydrolase (mEH) enzymes. The emphasis is on two main topics, the molecular genetics of the polymorphisms and the consequences for xenobiotic metabolism and toxicity. Studies are described in which wild-type and mutant alleles of biotransformation enzymes have been expressed in heterologous systems to study the molecular genetics and the metabolism and pharmacological or toxicological effects of xenobiotics. Furthermore, studies are described that have investigated the effects of genetic polymorphisms of biotransformation enzymes on the metabolism of drugs in humans and on the metabolism of genotoxic compounds in vivo as well. The effects of the polymorphisms are highly dependent on the enzyme systems involved and the compounds being metabolized. Several polymorphisms are described that also clearly influence the metabolism and effects of drugs and toxic compounds, in vivo in humans. Future perspectives in studies on genetic polymorphisms of biotransformation enzymes are also discussed. It is concluded that genetic polymorphisms of biotransformation enzymes are in a number of cases a major factor involved in the interindividual variability in xenobiotic metabolism and toxicity. This may lead to interindividual variability in efficacy of drugs and disease susceptibility.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10066160     DOI: 10.1080/10408449991349186

Source DB:  PubMed          Journal:  Crit Rev Toxicol        ISSN: 1040-8444            Impact factor:   5.635


  42 in total

1.  In vitro characterization of the human biotransformation pathways of aplidine, a novel marine anti-cancer drug.

Authors:  Esther F A Brandon; Rolf W Sparidans; Ronald D van Ooijen; Irma Meijerman; Luis Lopez Lazaro; Ignacio Manzanares; Jos H Beijnen; Jan H M Schellens
Journal:  Invest New Drugs       Date:  2007-02       Impact factor: 3.850

2.  Selection of antisense oligodeoxynucleotides against glutathione S-transferase Mu.

Authors:  Peter A C 't Hoen; Ruud Out; Jan N M Commandeur; Nico P E Vermeulen; F H D van Batenburg; Muthiah Manoharan; Theo J C van Berkel; Erik A L Biessen; Martin K Bijsterbosch
Journal:  RNA       Date:  2002-12       Impact factor: 4.942

3.  Drug-phytochemical interactions.

Authors:  Costas Ioannides
Journal:  Inflammopharmacology       Date:  2003       Impact factor: 4.473

Review 4.  Therapeutic drug monitoring and pharmacogenetic tests as tools in pharmacovigilance.

Authors:  Eveline Jaquenoud Sirot; Jan Willem van der Velden; Katharina Rentsch; Chin B Eap; Pierre Baumann
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

5.  In vitro characterization of the human biotransformation and CYP reaction phenotype of ET-743 (Yondelis, Trabectidin), a novel marine anti-cancer drug.

Authors:  Esther F A Brandon; Rolf W Sparidans; Kees-Jan Guijt; Sjoerd Löwenthal; Irma Meijerman; Jos H Beijnen; Jan H M Schellens
Journal:  Invest New Drugs       Date:  2006-01       Impact factor: 3.850

6.  CYP1B1 mutation profile of Iranian primary congenital glaucoma patients and associated haplotypes.

Authors:  Fereshteh Chitsazian; Betsabeh Khoramian Tusi; Elahe Elahi; Heidar Amini Saroei; Mohammad H Sanati; Shahin Yazdani; Mohammad Pakravan; Navid Nilforooshan; Yadollah Eslami; Mohammad Ali Zare Mehrjerdi; Reza Zareei; Mahmood Jabbarvand; Ali Abdolahi; Ali R Lasheyee; Arash Etemadi; Behnaz Bayat; Mehdi Sadeghi; Mohammad M Banoei; Behnam Ghafarzadeh; Mohammad R Rohani; Akram Rismanchian; Yvonne Thorstenson; Mansoor Sarfarazi
Journal:  J Mol Diagn       Date:  2007-07       Impact factor: 5.568

7.  Sulfotransferase 1A1 Arg(213)His polymorphism and prostate cancer risk.

Authors:  Serdal Arslan; Yavuz Silig; Hatice Pinarbasi
Journal:  Exp Ther Med       Date:  2011-08-12       Impact factor: 2.447

8.  Polymorphisms of glutathione S-transferase M1, T1 and P1 in patients with reflux esophagitis and Barrett's esophagus.

Authors:  Zdenek Kala; Jiří Dolina; Filip Marek; Lydie Izakovicova Holla
Journal:  J Hum Genet       Date:  2007-05-03       Impact factor: 3.172

9.  Interaction between GSTM1/GSTT1 polymorphism and blood mercury on birth weight.

Authors:  Bo-Eun Lee; Yun-Chul Hong; Hyesook Park; Mina Ha; Bon Sang Koo; Namsoo Chang; Young-Man Roh; Boong-Nyun Kim; Young-Ju Kim; Byung-Mi Kim; Seong-Joon Jo; Eun-Hee Ha
Journal:  Environ Health Perspect       Date:  2010-03       Impact factor: 9.031

10.  GSTT1, GSTM1 and CYP2E1 genetic polymorphisms in gastric cancer and chronic gastritis in a Brazilian population.

Authors:  Jucimara Colombo; Andréa Regina Baptista Rossit; Alaor Caetano; Aldenis Albaneze Borim; Durval Wornrath; Ana Elizabete Silva
Journal:  World J Gastroenterol       Date:  2004-05-01       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.